Cancer name Inflammatory Breast Cancer
Cancer Type BRCA
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment Cetuximab
Drugstatus Approved
Drugbank ID DB00002
Checkpoints NA
Signature Type Protein
Signature SRD5A1
Official Symbol SRD5A1
Mode of action TRAN_NR_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description Increased expression of transcripts related to oxidoreductase activity (GO:0016491) were observed in theXIAP-overexpressing lines, including plasma glutathioneperoxidase (GPX3), which metabolizes H2O2, theleukotriene-B4-degrading enzyme CYP4F3, the tryptophan-hydroxylating enzyme kynurenine 4-mono oxygenase and two hydrogenases involved in steroid synthesis of dihydrotestos-terone (SRD5A1) and dihydroxy progester one (DHRS9; allP≤0.01; ).
PMID 26821068
Title X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.